Latest HER2/neu Stories
HER3-positive circulating tumor cells home in on omentum; new target to thwart metastasis
ROCKVILLE, Md., July 2, 2014 /PRNewswire/ -- A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with
- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations NORTH CHICAGO, Ill.,
NEW YORK, June 17, 2014 /PRNewswire/ -- According to GLOBOCAN 2012, breast cancer was the second most commonly diagnosed form of cancer in 2012 with 1.7 million new cases, and accounting
DUBLIN, June 16, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bqwbck/companion) has announced the addition of the "Companion Diagnostics
ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted
OAKLAND, Calif., June 2, 2014 /PRNewswire/ -- Patients with specific HER2+ breast cancer tumors have a low risk of the cancer recurring five years after diagnosis, even without chemotherapy
WALTHAM, Mass., May 27, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual Meeting
Scientists at Cold Spring Harbor Laboratory (CSHL) today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer.
- The parings of haberdine; also, any kind of fragments.